Cancer genetics, precision prevention and a call to action

Area of Science:

• Genetics
• Oncology
• Genomic Medicine

Background:

• First-wave cancer susceptibility genes (e.g., BRCA1, BRCA2) identified via linkage have strong frequency-penetrance profiles.
• Second-wave genes (e.g., PALB2, ATM) identified through mutation screening have weaker profiles, complicating clinical application.
• Exome sequencing has revealed a polygenic architecture for common cancers, hindering 'next-wave' gene discovery.

Purpose of the Study:

• To evaluate the clinical utility and impact of different classes of cancer susceptibility genes.
• To propose a strategy for optimizing cancer control through genetic screening.
• To advocate for the implementation of national population-testing programs for high-impact gene mutations.

Main Methods:

• Review of genetic identification strategies for cancer susceptibility genes (linkage analysis, mutation screening, exome sequencing).
• Analysis of frequency-penetrance profiles to assess clinical utility.
• Evaluation of the 'genetic economics' of gene discovery and clinical impact.

Main Results:

• First-wave genes demonstrate significant clinical utility due to strong frequency-penetrance profiles.
• Second-wave and polygenic architectures present challenges for clinical application and gene discovery.
• Focused identification of first-wave gene mutation carriers is deemed most impactful for cancer control.

Conclusions:

• National population-testing programs for first-wave gene mutation carriers are recommended for precision cancer prevention.
• Long-term, large-scale studies with longitudinal data are necessary for comprehensive precision prevention.
• Prioritizing high-impact genetic targets is crucial for effective cancer management strategies.